跳至主要内容
临床试验/CTRI/2024/09/074525
CTRI/2024/09/074525尚未招募不适用

Adverse Drug Reaction monitoring in oncology patients receiving chemotherapy for generating safety indicators

Manipal Academy of Higher Education1 个研究点 分布在 1 个国家目标入组 150 人开始时间: 2024年10月1日最近更新:

试验速览

阶段
不适用
状态
尚未招募
入组人数
150
试验地点
1
主要终点
1.The incidence rate for ADRs in the study population will be identified.

研究概览

简要总结

A prospective, cross-sectional study will be conducted at the Department of Oncology (Medical Oncology, Surgical Oncology, Palliative Medicine, Pediatric and Radiotherapy) of Kasturba Hospital, Manipal. Patients will be identified in the oncology wards based on inclusion criteria. Throughout the duration of the study, consent will be obtained from the patients and confidentiality will be maintained. Patient case files will be assessed for identification of ADRs, and data will be collected according to the data collection form. Causality assessment of the ADRs will be done and their outcome will be studied. Indicators will be identified based on the ADRs found. Data analysis and interpretation will be done using Jamovi software.

研究设计

研究类型
Observational

入排标准

年龄范围
1.00 Year(s) 至 99.00 Year(s)(—)
性别
All

入选标准

  • Patients under chemotherapeutic regimen, developed ADR and willing to participate.

排除标准

  • Outpatients Not willing to participate in the study.

结局指标

主要结局

1.The incidence rate for ADRs in the study population will be identified.

时间窗: Just 1 time point after the participant has developed adverse drug reaction

2. The causality of ADRs will be identified.

时间窗: Just 1 time point after the participant has developed adverse drug reaction

次要结局

  • A list of indicators for ADRs will be identified(At the end of the study)

研究者

申办方类型
Other [PRIVATE UNIVERSITY]
责任方
Principal Investigator
主要研究者

Sriya Lingamagunta

Manipal College of Pharmaceutical Sciences

研究点 (1)

Loading locations...

相似试验